
Regulus Therapeutics RGLS
Regulus Therapeutics ROE Ratio | RGLS
Annual ROE Ratio Regulus Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -60.67 | -141.77 | -85.08 | -50.6 | -60.44 | -92.89 | 832.06 | -204.18 | -145.94 | -44.93 | -42.93 | -19.97 | -28.04 | - | 44.85 | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 832.06 | -204.18 | -7.18 |
Quarterly ROE Ratio Regulus Therapeutics
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -49.27 | -35.31 | -73.36 | -84.85 | -94.23 | -113.21 | -95.57 | -86.92 | -83.42 | -70.22 | -62.79 | -73.49 | -72.75 | -81.28 | -73.38 | -49.5 | -114.04 | -114.68 | -134.04 | 3664.12 | 3639.29 | 3645.82 | 3816.54 | -626.78 | -653.75 | -707.51 | -894.82 | -276.38 | -251.73 | -233.37 | -228.05 | -222.32 | -138.1 | -106.18 | -76.3 | -59.77 | -51.79 | -41.88 | -52.85 | -55.75 | -54.47 | -58.41 | -43.68 | -33.46 | -33.77 | -32.9 | -41.91 | -27.8 | -17.08 | -7.76 | 8.16 | -0.43 | -3.62 | 4.86 | 2.52 | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3816.54 | -894.82 | 148.84 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
NuCana plc
NCNA
|
-120.66 | $ 0.75 | 4.39 % | $ 8.42 B | ||
|
Novartis AG
NVS
|
30.0 | $ 150.51 | -0.47 % | $ 292 B | ||
|
Puma Biotechnology
PBYI
|
23.87 | $ 7.05 | -1.05 % | $ 353 M | ||
|
Fulcrum Therapeutics
FULC
|
-8.43 | $ 3.69 | -0.67 % | $ 281 M | ||
|
PDS Biotechnology Corporation
PDSB
|
-81.75 | $ 0.79 | -2.58 % | $ 36.6 M | ||
|
Geron Corporation
GERN
|
-36.97 | $ 0.87 | -4.76 % | $ 580 M | ||
|
Pharming Group N.V.
PHAR
|
22.12 | $ 11.54 | -5.18 % | $ 7.95 B | ||
|
Phathom Pharmaceuticals
PHAT
|
0.05 | $ 4.65 | -8.46 % | $ 339 M | ||
|
Genmab A/S
GMAB
|
21.38 | $ 50.36 | -1.93 % | $ 3.26 B | ||
|
Gossamer Bio
GOSS
|
138.78 | $ 10.69 | -4.81 % | $ 2.44 B | ||
|
Grifols, S.A.
GRFS
|
2.47 | $ 8.14 | -0.73 % | $ 5.53 B | ||
|
Liquidia Corporation
LQDA
|
-154.03 | $ 54.39 | -3.96 % | $ 4.68 B | ||
|
GlaxoSmithKline plc
GSK
|
39.41 | $ 47.8 | -0.05 % | $ 194 B | ||
|
MediciNova
MNOV
|
28.85 | $ 1.3 | 2.36 % | $ 63.8 M | ||
|
PTC Therapeutics
PTCT
|
-332.66 | $ 56.23 | -3.59 % | $ 4.47 B | ||
|
Pulmatrix
PULM
|
-32.64 | $ 1.24 | -12.34 % | $ 4.53 B | ||
|
InflaRx N.V.
IFRX
|
-109.81 | $ 1.05 | -3.67 % | $ 70.7 M | ||
|
Immunome
IMNM
|
-33.48 | $ 15.69 | -5.54 % | $ 1.37 B | ||
|
Immuron Limited
IMRN
|
-64.64 | $ 0.9 | 5.87 % | $ 208 M | ||
|
Incyte Corporation
INCY
|
24.9 | $ 114.5 | -1.19 % | $ 22.4 B | ||
|
INmune Bio
INMB
|
-195.54 | $ 0.82 | -8.41 % | $ 20.3 M | ||
|
Dr. Reddy's Laboratories Limited
RDY
|
16.98 | $ 14.88 | 0.24 % | $ 12.4 B | ||
|
Regeneron Pharmaceuticals
REGN
|
14.41 | $ 920.38 | -0.22 % | $ 96.3 B | ||
|
Ionis Pharmaceuticals
IONS
|
-77.98 | $ 26.58 | -2.37 % | $ 4.25 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
63.85 | $ 1.06 | -10.92 % | $ 48.4 M | ||
|
Ironwood Pharmaceuticals
IRWD
|
-9.17 | $ 4.68 | -0.53 % | $ 757 M | ||
|
Kala Pharmaceuticals
KALA
|
-385.65 | $ 2.73 | -9.61 % | $ 22.2 M | ||
|
Intellia Therapeutics
NTLA
|
-61.47 | $ 10.02 | 5.24 % | $ 1.09 B | ||
|
Adagene
ADAG
|
-49.82 | $ 1.8 | -10.56 % | $ 106 M | ||
|
Denali Therapeutics
DNLI
|
-50.56 | $ 18.43 | 1.29 % | $ 3.18 B | ||
|
Pfizer
PFE
|
8.99 | $ 27.4 | -0.62 % | $ 156 B | ||
|
Amarin Corporation plc
AMRN
|
-8.45 | $ 10.56 | -6.26 % | $ 4.38 B | ||
|
ImmuCell Corporation
ICCC
|
-3.84 | $ 11.08 | -0.81 % | $ 100 M | ||
|
Editas Medicine
EDIT
|
-586.56 | $ 1.63 | -4.68 % | $ 145 M | ||
|
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
10.4 | $ 93.83 | 0.32 % | $ 6.96 B | ||
|
Agios Pharmaceuticals
AGIO
|
-34.62 | $ 27.54 | -4.24 % | $ 1.6 B | ||
|
Royalty Pharma plc
RPRX
|
7.94 | $ 68.45 | 1.08 % | $ 29.4 B | ||
|
Equillium
EQ
|
-78.32 | $ 1.06 | -5.36 % | $ 60.7 M | ||
|
Black Diamond Therapeutics
BDTX
|
19932.98 | $ 1.32 | -5.04 % | $ 75.1 M | ||
|
Abeona Therapeutics
ABEO
|
-44.71 | $ 2.42 | -1.17 % | $ 128 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
31.86 | $ 17.1 | -2.79 % | $ 2.88 B | ||
|
Atossa Therapeutics
ATOS
|
-88.35 | $ 1.6 | -8.86 % | $ 13.8 M | ||
|
Cleveland BioLabs, Inc.
CBLI
|
-119.12 | - | -7.31 % | $ 49 M | ||
|
Rhythm Pharmaceuticals
RYTM
|
-0.14 | $ 112.31 | -3.84 % | $ 7.3 B | ||
|
Five Prime Therapeutics, Inc.
FPRX
|
-31.81 | - | - | $ 1.77 B | ||
|
ADC Therapeutics SA
ADCT
|
76.74 | $ 1.29 | -2.28 % | $ 164 M | ||
|
Harmony Biosciences Holdings
HRMY
|
18.24 | $ 32.58 | -1.21 % | $ 1.87 B | ||
|
Ardelyx
ARDX
|
-37.14 | $ 2.99 | -2.25 % | $ 721 M | ||
|
Akebia Therapeutics
AKBA
|
-16.25 | $ 0.39 | -8.41 % | $ 100 M | ||
|
Alector
ALEC
|
-466.57 | $ 2.34 | 1.52 % | $ 241 M |